MBX Biosciences (MBX) Net Income towards Common Stockholders (2023 - 2026)
MBX Biosciences (MBX) reported Net Income towards Common Stockholders of -$23.5 million for Q1 2026, up 1.52% on a YoY basis from -$23.2 million in Q1 2025, and down 6.6% sequentially from -$22.1 million in Q4 2025.
MBX Biosciences (MBX) Net Income towards Common Stockholders (2023 - 2026) Analysis & Trends
MBX Biosciences (MBX) has 4 years of Net Income towards Common Stockholders data on file, last reported at -$23.5 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 1.52% year-over-year to -$23.5 million; the trailing twelve-month figure through Mar 2026 stood at -$86.6 million (down 17.89% YoY), and the FY2025 full-year result was -$87.0 million, down 40.45% from the prior year.
- Net Income towards Common Stockholders eased to -$23.5 million in Q1 2026, from -$22.1 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$8.8 million in Q4 2023 to a low of -$23.9 million in Q1 2025.
- A 4-year average of -$17.4 million and a median of -$18.1 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders tumbled 93.56% in 2025 and increased 1.52% in 2026, its largest moves.
- Tracing MBX's Net Income towards Common Stockholders over 4 years: stood at -$8.8 million in 2023, then slumped by 76.25% to -$15.6 million in 2024, then tumbled by 41.55% to -$22.1 million in 2025, then slipped by 6.6% to -$23.5 million in 2026.
- Business Quant data shows MBX's Net Income towards Common Stockholders at -$23.5 million in Q1 2026, -$22.1 million in Q4 2025, and -$21.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,924.26 Bn | 1,924.20 Bn | - | - |
| 3 | Akari Therapeutics | 975.59 Bn | 975.59 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.47 Bn | 466.67 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.76 Bn | 114.52 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.15 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.83 Bn | 62.83 Bn | - | -0.68 |
| 8 | Argenx Se | 55.77 Bn | 50.59 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.45 Bn | 37.45 Bn | - | -453.82 Mn |
| 10 | MBX Biosciences | 2.86 Bn | 2.86 Bn | - | -23.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.52 Mn |
| Dec 31, 2025 | -22.06 Mn |
| Sep 30, 2025 | -21.62 Mn |
| Jun 30, 2025 | -19.41 Mn |
| Mar 31, 2025 | -23.88 Mn |
| Dec 31, 2024 | -15.59 Mn |
| Sep 30, 2024 | -18.14 Mn |
| Jun 30, 2024 | -15.86 Mn |
| Mar 31, 2024 | -12.34 Mn |
| Dec 31, 2023 | -8.84 Mn |
| Sep 30, 2023 | -10.16 Mn |